Introducing our dynamic team of experienced entrepreneurs, seasoned venture capitalists, innovative university faculty, and corporate leaders who are ready to delve into ‘what you don’t know you don’t know’ about venturing new businesses.
Evan Anderson received his BS in Biomedical Engineering with a concentration in Material Science and a minor in Psychology from Johns Hopkins University in 1998. As an undergraduate, he did research for the Food and Drug Administration on the physiological conditions of implantable devices and assessed orthopedic bone screw designs for knee surgery at Union Memorial Hospital. During the summer of 1998, Evan worked as product development intern at Johnson and Johnson and evaluated new materials for an Internal Sanitary Protection product. While pursuing his MS degree in Biomedical Engineering at Case Western Reserve University, Evan performed research on the mechanics of heart valves at the Cleveland Clinic Foundation. For his graduate thesis he designed a patent pending fatigue tester for bioprosthetic heart valve tissue. As an R&D engineer at Guidant Corporation since 2001 and now Boston Scientific, Evan has worked on development of a next generation implant for Abdominal Aortic Aneurysms with catheter based delivery and development of a first generation proximal anastomosis clip for off-pump cardiac bypass surgery. In December of 2001, Evan organized and chaired a three-day conference on medical device innovation in which 4th year medical students and Bay Area design professionals collaborated on identifying targeted needs for medical device development. While at Guidant Corporation, Evan completed classes at Stanford University towards a Certificate in Product Creation and Innovative Manufacturing. After finishing the Stanford Biodesign Innovation Program Evan spent three months at the FDA in the Medical Device Fellowship Program working as a Biomedical Engineer. Most recently he has returned to Guidant as an R&D Engineer in Cardiac Surgery.
Angel is the Product Marketing Manager
for Abbott Vascular's Drug Eluting Stent
in the Asia Pacific region. Before moving
to Hong Kong for this role, Aimee was in
the Strategic Marketing and New Product
Planning group at Abbott, where she is
responsible for their next generation drug-eluting
stent. Prior to joining Abbott, Aimee was
a Venture Associate at De Novo Ventures
assessing medical device investment opportunities,
negotiating deal structures, and assisting
portfolio companies after investment. Aimee
completed her BS and MS degrees in Mechanical
Engineering at MIT, and was named the John
B. Simpson, PhD, MD Fellow in the Biodesign
Innovation Program at Stanford University,
where she worked to develop medical devices
to treat cardiovascular disease. Her work
has resulted in a number of patent applications
that are currently under development.
Roger Anderson Managing Partner BioQuest, LLC
As co-founder and managing partner of BioQuest, LLC, Roger Anderson sets the highest standards for client service for the firm. His vision and commitment to excellence provide the platform for the BioQuest service model, which, over the last 20 years, has helped grow the firm into one of the leading specialty executive search firms in the United States. Roger’s practice is focused on the medical device sector, conducting searches at the CEO and VP levels. Prior to entering the executive search field in 1981, Roger had ten years of successful medical device sales with, IVAC Corporation (now Alaris Medical) and American Hospital Supply (McGaw Laboratories Div). He received his BS in Biological Sciences from the University of Wisconsin, followed by four years as a US Naval Officer.
Amir Belson CTO, Co-Founder NeoGuide Systems
Amir Belson, M.D., is the chief technology officer, co-founder, and member of the board of directors of NeoGuide Systems, a company delivering platform technology that transforms the way endoscopic procedures are conducted. The company's technology is based on Dr. Belson's intellectual property. Dr. Belson graduated cum laude from the Technion School of Medicine, Israel Institute of Technology in Haifa, Israel. He did his pediatric residency at Dana Children's Hospital in Tel Aviv and his pediatric nephrology fellowship at Lucile Packard Children's Hospital at Stanford. Dr. Belson also spent one year as a research fellow with the Biomedical Technology Innovation Program at Stanford. He is the author of 34 medical papers and abstracts and has 70 issued and pending patents. Dr. Belson is also the founder of Vascular Pathways, a vascular intervention company; and Thermocure, a therapeutic hypothermia technology company.
Jeffery Bleich Founder, CEO Baxano Inc.
Dr. Jeffery Bleich is the founder and CEO of Baxano Inc., an early stage medical device company developing minimally invasive tools that restore spine function and preserve healthy tissue. He has 20 years of clinical experience, with board certification in Pain Management, as well as in Anesthesiology. Dr. Bleich currently practices anesthesiology at Stanford University Medical Center. Before Baxano, he was an executive in residence with Prospect Venture Partners, a healthcare dedicated venture capital fund. Prior to Prospect, he worked in medical device design at IDEO.
Dr. Bleich completed a Masters Degree as a Sloan Fellow at the Stanford Graduate School of Business, a Pain Management fellowship at the University of Washington, an anesthesiology residency at UCLA, an M.D. from the University of Texas, Southwestern Medical School, and a B.S. in biology from Stanford University.
Daniel Bloch Professor, Health Research & Policy Stanford University
Daniel A. Bloch, PhD is Professor of Health Research and Policy at Stanford University in the Division of Biostatistics. He has more than 200 peer-reviewed publications and is a Member of the Editorial Board for scientific journals Osteoarthritis and Cartilage and the Journal of Endovascular Therapy. Dr. Bloch is a Consultant to the VA Cooperative Studies Coordinating Center. He received his Bachelor’s Degree in Statistics from Stanford University and his Doctorate in Statistics from John’s Hopkins University.
Leslie Bottorff joined ONSET Ventures in 1998 after 19 years in the medical industry. At ONSET Ventures, Leslie specializes in medical technology investment opportunities. She has worked closely with several portfolio company entrepreneurs at the seed stage to formulate and validate their companies' business plans, including Curon Medical, Novasys Medical and Embolic Protection, where she was interim VP of Marketing and Business Development at inception. Leslie has served in board or advisory roles for several portfolio companies including Spinal Concepts, Novasys Medical, VisionCare Ophthalmic Technologies, Neuronetics, Sadra Medical and CardioMind.
Prior to joining ONSET, Leslie was VP of Sales and Marketing of Medtronic’s CardioRhythm division. She has also served in various marketing and sales management positions at both venture backed start-up companies and in large companies, including Nellcor, Ventritex, Menlo Care and General Electric's Medical Systems division.
Leslie has a B.S. in Biomedical Engineering from Purdue University and an MBA from Harvard Business School. She serves on advisory boards or as program faculty at several universities, including Stanford University and Purdue University.
Todd Brinton Instructor, Medicine, Bioengineering Stanford University
Dr. Todd Brinton is an instructor in medicine and bioengineering at Stanford University. He is an attending interventional cardiologist at both the Palo Alto VA Medical Center and Stanford University Medical Center. He is also the fellowship director for the program in biodesign innovation and co-director of the graduate class in biodesign innovation. His responsibilities include coaching and mentorship of the innovation fellows and direction of the graduate course in biodesign innovation. Dr. Brintons academic research focuses on the development and evaluation of techniques for cardiac stem cell transplantation and imaging techniques for assessment of cell viability after transplant in pre-clinical models. He is also active in clinical trials of interventional-based therapies for chronic ischemia and heart failure.
He received his B.S. in Biomedical Engineering from University of California, San Diego in 1992. From 1991-1993 he worked as an R&D engineer for an early-stage medical device company focused on non-invasive hemodynamic monitoring. From 1994-1996 he directed clinical research and development for the same company and authored patents and peer-reviewed publications related to the non-invasive assessment of vessel compliance, left ventricle contractility, and aortic insufficiency. He completed his doctorate in medicine at The Chicago Medical School and graduated with Alpha Omega Alpha honors in 2000. He completed his internal medicine training at Stanford and in 2002 was accepted into the cardiology fellowship program at Stanford under the clinical investigator pathway. He completed his clinical cardiology fellowship in 2004. He served as chief fellow in cardiology at Stanford from 2004-2005 and completed a specialty fellowship in Biodesign in 2005. He completed an interventional cardiology fellowship at Stanford in 2006.
Byers has been a venture capital investor since
1972. He has been closely involved with more
than forty new technology based ventures, over
half of which have already become public companies.
He formed the first Life Sciences practice
group in the venture capital profession in
1984 and led KPCB to become a premier venture
capital firm in the medical, healthcare, and
biotechnology sectors. KPCB has invested in
and helped build over 90 Life Sciences companies
which are developing hundreds of products to
treat major underserved medical needs representing
huge markets in the nearly two trillion dollar
Brook was the founding President, and then
Chairman, of four biotechnology companies which
were incubated in KPCB's offices and went on
to become public companies with an aggregate
market value over $8 billion. He is currently
on the Board of Directors of eight companies,
most recently joining CardioDX, Genomic Health
Incorporated, Five Prime Therapeutics, Pacific
Biosciences, Inc. and XDx, Inc. He was formerly
a Director of Idec Pharmaceuticals (Chairman),
Athena Neurosciences (Chairman), Signal Pharmaceuticals,
Arris Pharmaceuticals, Pharmacopeia, Ligand
Pharmaceuticals (Chairman), Hybritech (Chairman),
Genprobe, Nanogen, and others. These companies
have pioneered the medical uses of molecular
biology, monoclonal antibodies, molecular diagnostics
Brook was President and a Director of the
Western Association of Venture Capitalists
and is a contributing author of the book “Guide
to Venture Capital”. He is currently
a Board member of the University of California
at San Francisco Medical Foundation, the California
Healthcare Institute, the New Schools Foundation,
Stanford’s Bio-X Advisory Council, the
Stanford Eye Council and TechNet. He is Co-Chair
of the current five year, $1.4 billion, UCSF
Capital Campaign. He was formerly a Director
of the Entrepreneurs Foundation, the Asian
Art Museum in San Francisco, the Stanford Graduate
School of Business Advisory Council, That Man
May See (UCSF) Vision Research Foundation (Chairman)
and the Georgia Tech Advisory Board. Raised
in Atlanta, Georgia, Brook graduated in Electrical
Engineering from Georgia Tech and received
an MBA from Stanford.
Colin Cahill received a B.S. in Biological Sciences and a B.A. in Economics from Stanford University in 1998. As an undergraduate, Colin interned at Cor Therapeutics (laboratory assistant) and Sangamo BioSciences (corporate development). After graduating, Colin joined the Boston Consulting Group (BCG), where he helped develop solutions to strategic and operational problems for pharmaceutical companies in the U.S. and Europe. In addition to client service projects, Colin worked with a small team on behalf of BCG to launch an internet marketplace for life science intellectual property. Following BCG, Colin became Director of Business Development and Co-Founder of Cellicon Biotechnologies, a Boston-based drug discovery company aiming to develop new antibiotics using a technology platform that can rapidly map complex biological networks. Colin also led several business development projects for Israeli medical technology companies while working for PureTech Development. Colin completed an M.S. in Biological Sciences at Stanford University and an MBA from Stanford's Graduate School of Business. He is currently involved in a medical device start-up.
Advanced Technology Ventures
joined ATV in 1998, and focuses on investments
in the life sciences and medical device sectors.
His representative investments include Emphasys
Medical, EndoGastric Solutions, GI Dynamics,
GluMetrics, NeuroVista, Plexxikon, TranS1,
Xtent (NASDAQ: XTNT), and MicroVention (acquired
Mike brings over a decade of operational and
management consulting experience to ATV. Prior
to joining ATV, Mike served as the Director
of Business Development for Inhale Therapeutic
Systems (now Nektar Therapeutics NASDAQ: NKTR),
a venture-backed pulmonary drug delivery company
that went public in 1994. At Inhale, Mike led
partnering activities with a number of well-established
pharmaceutical and biotechnology companies
in the U.S., Europe and Japan. Mike was also
a Principal at The Wilkerson Group, a strategic
ATV partner and leading management consulting
firm focused exclusively on healthcare. At
The Wilkerson Group, Mike helped establish
the firm’s offices in London and San
Mike holds an M.B.A. from the Amos Tuck School
of Business Administration at Dartmouth College
and a B.S. from Lehigh University.
Kathryn joined De Novo Ventures in September 2005. Prior to De Novo, Kathryn worked for Merck & Co., Inc from 1997-2003 in the US, Europe and Asia. Her experience includes process engineering, equipment and automation design, procurement, process validation, plant construction and operations. At Merck, she played a key role in the design, construction, commissioning and start up of a $400 MM grassroots bulk chemical manufacturing facility in Singapore, Merck’s first new site in 40 years. On this project, Kathryn led the design of $30 MM of large scale automated manufacturing equipment from inception through start-up production, while stationed in England and Singapore for five years. In this role, she oversaw several multinational cross-functional teams to expedite project issues, resulting in the successful on-time start-up of the Singapore facility. In addition, Kathryn worked at Genentech in strategic planning and operations strategy. Working closely with Marketing, Finance, R&D and Manufacturing, she performed capacity planning for E.coli product pipelines and identified potential spin-out candidates in light of operational, regulatory and investment risks.
Kathryn is a graduate of the University of Notre Dame with Bachelor of Science degrees in Chemical Engineering and Biochemistry. She holds an M.B.A. from Harvard Business School.
Morrison & Foerster
E. Ciotti is a partner and co-founder of the
Venture Intellectual Property group, and founder
of the biotechnology/chemistry, medical device,
and greentech patent groups at Morrison & Foerster LLP.
Mr. Ciotti has over 40 years of experience
in life sciences intellectual property law
and is regularly acknowledged by his peers
as one of the top life sciences intellectual
property lawyers in the United States. Mr.
Ciotti is one of a distinguished group of attorneys
who have been listed in The Best Lawyers in
America for ten years. He was one of the first
biotechnology patent attorneys and represented,
and continues to represent, universities and
corporations that pioneered the field of biotechnology.
For many years Mr. Ciotti’s practice
revolved around counseling emerging life science
companies, not only in the chemistry/biotech
field, but also in the medical device field.
In the course of doing so, he has served as
principal intellectual property counsel to
numerous biotechnology and medical device companies.
Due diligence counseling from both the investor
and company sides has always been a significant
part of his practice. In recent years venture
side due diligence has become the mainstay
of Mr. Ciotti’s practice and a critical
and important part of Morrison & Foerster’s
intellectual property practice. With the recent
interest in renewable energy/cleantech by the
venture capital community, Mr. Ciotti's practice
has grown to include those technologies. Mr.
Ciotti holds chemical engineering and law degrees
from the University of Michigan. He was president
of the San Francisco Intellectual Property
Law Association and has served as chairman
of the Intellectual Property Section of the
State Bar of California.
Craig Coombs Head Coombs Medical Device Consulting
Craig Coombs has been the head of Coombs Medical Device Consulting since 1998. His group specializes in hands-on, innovative, US and European regulatory strategies for start-ups and companies that need to change their business strategies. Their skills also include cost-effective first-in-man or VC milestone clinical trial design, management and analysis. Mr. Coombs received his BS in Biology from Stanford University. He is a former Vice President of Medtronic in the areas of Regulatory Affairs, Quality Assurance and Clinical Studies. Mr. Coombs is an instructor in Medical Devices for the University of California at Santa Cruz.
Jack Costello Russell Reynolds Associates’ Medical Technology, Devices and Diagnostics Practice
Jack Costello leads Russell Reynolds Associates’ Medical Technology, Devices and Diagnostics Practice in the Americas. Based in Chicago, he has completed numerous searches for chief executive officers, board directors and functional executives for device clients.
Jack has more than five years of executive search experience. Formerly, Jack served for 18 years as an executive at multinational medical device companies, Johnson & Johnson, Medtronic and Baxter. Earlier he was a senior officer at the start-up companies Cardiovascular Imaging Systems (acquired by Boston Scientific Corporation) and Urologix.
Jack is the co-founder of The Leaders Forum for high-potential executives who are charting the future course of innovation in the medical device industry. The group was co-founded with Versant Ventures, a leading life science venture firm, and Wilson Sonsini Goodrich & Rosati, a high-technology law firm.
Jack received his B.A. in biology from St. Joseph’s College.
Rajiv Doshi Founder, CEO Venus Medical
Rajiv Doshi, MD is the Executive Director of the new (2007) Stanford-India Biodesign Initiative. He is also Founder and CEO of Ventus Medical, a venture capital-backed pulmonary device startup in Woodside, CA. Prior to founding Ventus, he was a Principal at De Novo Ventures where he served as a board member or observer for Ovalis, Spinal Kinetics and Paracor. A Lecturer in the Stanford University Department of Medicine, Rajiv also co-teaches two medical device design courses. The first, “Medical Device Design” is a prototyping-intensive, graduate level course within the Department of Mechanical Engineering. The second, “Medical Device Innovation” is an undergraduate course within the Department of Bioengineering that teaches the fundamentals of medical device entrepreneurship. Rajiv earned a BS in chemical engineering, an MSE in biomechanical engineering, and an MD, all from Stanford University. He also serves on the Medical Advisory Board of Lunar Design. Rajiv has roughly twenty US patents issued or pending.
David L. Douglass
Since 1979, David has been actively involved in managing and investing in over 50 high growth venture capital backed companies, primarily in the medical device industry. He joined Delphi Ventures in 1990. Prior to joining Delphi, David was a General Partner at Matrix Partners focusing on medical device investments.
From 1984 to 1986, David served as Chief Operating Officer at Paladin Software Corporation, responsible for operations, R&D, finance and administration. From 1979 to 1983, David served as Vice President of Finance and Administration at Collagen Corporation. He was responsible for several private equity financings, as well as Collagen's initial public offering. Before joining Collagen, David was a consultant with McKinsey & Company.
David has served as a Director of the Western Association of Venture Capital and presently serves as a director of the Stanford University Athletic Board and as a member of the Stanford University School of Education Advisory Board. Additionally, in 2005, David was named to Forbes Midas List identifying the top 100 dealmakers in the venture capital industry.
Erik Engelson joined Cierra from Fluidigm Corporation where he was the Chief Financial Officer. Prior to joining Fluidigm, Mr. Engelson was a Venture Partner at Versant Ventures, and had previously been an Entrepreneur-in-Residence at Institutional Venture Partners. Previously, Mr. Engelson spent 13 years in various operating roles at Target Therapeutics where he led the early start-up into the field of Interventional Neuroradiology and eventually became its General Manager. He is the inventor of many medical device patents, and is the recipient of the 1998 Inventor of the Year Award from the Silicon Valley Intellectual Property Law Association. Mr. Engelson currently serves on the Board of Directors of Concentric Medical and Primaeva Medical, and is a co-founder of FlowCardia. Mr. Engelson holds B.S. and M.S. degrees in Microbiology and Bioengineering, respectively, from the University of California, San Diego, and has completed the Stanford Executive Program. Mr. Engelson is a Trustee of the U.C. San Diego Foundation.
Rich Ferrari Managing Director De Novo Ventures
Rich Ferrari is a Managing Director at De Novo Ventures. Rich has been a successful CEO of several medical technology companies, both prior to and after co-founding De Novo in 2000. Following De Novo’s investment in Cryovascular Systems, Rich became CEO, growing the initial 5 person start up team to a company of 20 employees. He was instrumental in developing the clinical and product strategies and hiring the executive team. In 2002, Rich led Paracor Medical, another De Novo portfolio company. He grew the company from 4 to 22 employees, refined the product strategy, raised its Series B financing and hired his replacement CEO. Prior to co-founding De Novo Ventures, he was the co-founder and CEO of CardioThoracic Systems (“CTSI”), a company he led to an initial public offering in only 7 months in 1996. CTSI, the market leader in disposable instruments and systems for performing minimally invasive beating heart bypass surgery, was ultimately acquired by Guidant Corporation in November 1999. Before that, Rich was the CEO of Cardiovascular Imaging Systems (“CVIS”). As CEO, he orchestrated a successful IPO and ultimately sold the company to Boston Scientific Corporation in 1995. In addition, he founded Saratoga Ventures in 1996, a venture capital partnership that has provided seed financing to startup medical technology companies, including Atrionix, Oratec, Enteric Medical, Trivascular, and Endotex. At Saratoga, Rich was Chairman of Oratec, which was sold in 2001 to Smith & Nephew PLC. Mr. Ferrari also co-founded The Medical Technology Group, which spun out Integrated Vascular Systems, an early stage femoral artery closure company which was sold to Abbott and Angiosense, a needle-free, jet injection, local drug delivery company. Early in his career, Rich held the position of Executive Vice President and General Manager of ADAC Laboratories. Rich holds a BS degree from Ashland University and an MBA from the University of South Florida.
Frank Fischer CEO NeuroPace
Frank Fischer has more than 25 years of senior management experience in the medical device industry. He has served on the NeuroPace Board of Directors since 1998 and joined the Company as its Chief Executive Officer in January 2000. Prior to joining NeuroPace, Mr. Fischer was President and Chief Executive Officer of Heartport, Inc., a cardiac surgery company, from May 1998 until September 1999 and served on Heartport’s Board of Directors. Mr. Fischer was President and Chief Executive Officer and a director of Ventritex, Inc., a company that pioneered implantable cardiac defibrillators, from 1987 until the sale of the company to St. Jude Medical, Inc. in 1997. Before joining Ventritex, he spent ten years in various management positions at Cordis Corporation in the cardiac and neurosurgical device areas, serving most recently as President of the Implantable Products Division. Prior to that, he spent seven years with General Electric Company in a variety of operating positions. Mr. Fischer holds B.S.M.E. and M.S. in Management degrees from Rensselaer Polytechnic Institute. Currently, he also serves on the boards of a number of privately held medical device companies.
Thomas Fogarty Fogarty Engineering
Dr. Thomas J. Fogarty is an internationally recognized cardiovascular surgeon, inventor, entrepreneur, and vintner. He has been involved with a wide spectrum of innovations in business and technology, serving as founder/co-founder, and Chairman/Board Member of over 33 various business and research companies, based on devices designed and developed by Fogarty Engineering, Inc. During the past 40 years, he has acquired over 100 surgical patents, including the “industry standard” Fogarty balloon embolectomy catheter and the widely used Aneurx Stent Graft that replaces open-heart abdominal aortic aneurysm (AAA) surgery. Dr. Fogarty is the recipient of countless awards and honors; most significantly, he is the recipient of the Jacobson Innovation Award of the American College of Surgeons, the 2000 Lemelson-MIT prize for Invention and Innovation and was inducted into the Inventors Hall of Fame in December 2001.
Dr. Fogarty was born in Cincinnati, Ohio and received his undergraduate education at Xavier University and his medical degree from the University of Cincinnati. He completed his residency at the University of Oregon and later served as Medical Staff President at Stanford Medical Center from 1973-1975. After thirteen years directing the Cardiovascular Surgery Program at Sequoia Hospital, Redwood City, California, he returned to academic life at Stanford University School of Medicine in July 1993, as Professor of Surgery. Dr. Fogarty resigned from Stanford in 2001 and now spends a majority of his time creating new medical devices with Fogarty Engineering.
David Forster President, CEO AorTx Inc.
David C. Forster has over 25 years of dedicated medical device experience in both large cap public companies as well as privately financed companies. Mr. Forster is the founder of AorTx, a percutaneous Aortic heart valve company and the primary inventor of the AorTx technology. Mr. Forster has served as the President and CEO of AorTx Inc. since October 2003. Prior to that Mr. Forster has served in technical management positions with Pacific Consultants, a medical device consulting firm with over 100 highly trained and educated technical consultants, Guidant, Eli Lilly, Origin Medsystems, and Varian Medical Imaging. Mr. Forster is listed on approximately 25 patents, and is a licensed Professional Mechanical Engineer in the state of California. In addition to serving on the Board of Directors of AorTx, Mr. Forster has served on the boards of Kings Grove and the Cabrillo Unified School District.
Michael Gertner President, CEO Oraya Therapeutics
Dr. Micheal Gertner is currently the President and CEO of Oraya Therapeutics, a venture backed company which he founded in 2006. He is a consultant to the Biodesign Program, to the Department of Surgery at Stanford, and to the Department of Surgery at Santa Clara Valley Medical Center.
Dr. Gertner completed a BS and an MS in mechanical engineering from Columbia and MIT and attended medical school at Cornell. He then attended UCSF through a chief residency in General Surgery. He is currently board certified in general surgery. In addition to Oraya, Dr. Gertner is the founder or co-founder of Medlogics Device Corporation, Allux Medical, Minimus Surgical Systems, Hydrocardia, and Gem Biosystems. He also serves on the board of directors of Stratagent Lifesciences and Nellix Medical.
Paul Goeld President, CEO Intuity Medical
Paul Goeld is currently President and CEO of Intuity Medical, a private, venture-backed company that is developing a new blood glucose meter for the diabetes market. Paul was previously President and CEO of Adiana, Inc., a women’s health care company that was acquired by Cytyc Corporation in March 2007. Prior to Adiana, Paul held executive or board positions with LocalMed, Pilot Cardiovascular Systems, Camino Laboratories, General Surgical Innovations and InnerDyne. Paul is Chairman of Gynesonics and Aegea Medical and is a director of BAROnova and Bioventrix.
Jeff Gold Venture Partner Longitude Capital
Jeff Gold is a Venture Partner of Longitude Capital. He focuses on investments in medical devices. Prior to Longitude, Mr. Gold was Chief Executive Officer of CryoVascular Systems, a medical device company developing treatments for peripheral vascular disease, from 2001 to 2005. CryoVascular Systems was acquired by Boston Scientific Corporation in 2005. Mr. Gold and Ms. Tammenoms Bakker worked together on the CryoVascular Systems board of directors between 2000 and 2005. Between 1997 and 2000, Mr. Gold was COO and Executive Vice President of CardioThoracic Systems (NASDAQ: CTSI), a medical device company focused on developing products to enable off-pump open-heart surgery. CTSI completed an IPO in 1996 and was subsequently acquired by Guidant Corporation. Prior to CTSI, Mr. Gold spent 18 years with Cordis Corporation, now the primary cardiovascular subsidiary of Johnson & Johnson. He currently sits on the boards of Access Closure, AngioDynamics (NASDAQ: ANGO), Voyage Medical, and Niagara Gorge Medical Devices. He also is a member of the Executive Committee of the Center for Entrepreneurship & Innovation at the University of Florida and a member of the Device Screening Committee for the Life Science Angels. Mr. Gold holds an M.B.A. from the University of Florida and a B.S. in Engineering from Northeastern University, and is a graduate of GE’s Manufacturing Management Program.
Linda Grais InterWest Partners
Linda Grais, M.D., brings to InterWest Partners a wide array of experience as a physician, attorney and biotechnology entrepreneur.
Previously, Dr. Grais was a founder and executive vice president of SGX Pharmaceuticals (SGXP), a drug discovery company focusing on new treatments for cancer. Prior to that, she was a corporate attorney at Wilson Sonsini Goodrich & Rosati, where she represented biotechnology and medical device companies in venture financings, public offerings and strategic partnerships.
Before practicing law, Dr. Grais worked as an assistant clinical professor of Internal Medicine and Critical Care at the University of California, San Francisco. She has also served as a consultant to the Institute of Medicine, and is a member of the Stanford Law School Board of Visitors.
Dr. Grais received a B.A. from Yale University, magna cum laude, and Phi Beta Kappa, an M.D. from Yale Medical School, and a J.D. from Stanford Law School.
Grossman M.D. is Founder and CEO of Gynesonics, a
silicon valley based medical device company
focused on the women’s health care market. Dr.
Grossman had worked at a number of Bay Area
medical technology companies and has several
publications in numerous scientific journals.
Dr. Grossman graduated from Brandeis University
in 1994 and then received her graduate degree
in medicine from Thomas Jefferson Medical College
in 1999. She completed her internship
in obstetrics and gynecology at Pennsylvania
Hospital in 2000 and then moved to San Francisco
to pursue a career in the medical device industry.
Ken Haas Venture Partner Abignworth
Ken Haas, Venture Partner, has spent 25 years in the management of both early-stage and public high technology and biotechnology companies. He was part of the founding management team at IntelliGenetics, one of the world’s first bioinformatics companies and, from 1992 to 2001, was CEO of IntelliCorp, a publicly-traded enterprise software company. At the beginning of his career he practiced as an attorney in the business and technology group of Heller, Ehrman, White & McAuliffe. He is currently Co-Chair of the Advisory Council to the Neuroscience Institute at Stanford. Ken received his BA from Harvard College, an MA from the University of Sussex, a JD from Harvard Law School and attended the Advanced Management Program at Harvard Business School. He has been with Abingworth since October 2004 and is based in Menlo Park.
John Harris President, CEO NeuroVista
John F. Harris, President and CEO of NeuroVista, has over 20 years of experience successfully developing and commercializing innovative medical device technologies. Prior to joining NeuroVista in December of 2004, John was an Executive in Residence (EIR) at Versant Ventures, a healthcare-dedicated venture capital firm, providing consulting on early stage medical device opportunities.
Prior to his work with Versant Ventures, John was a founder and the Vice President of Marketing and Business Development for Northstar Neuroscience, a Seattle-based medical device company seeking to improve neurological recovery following stroke through targeted electrical stimulation of the brain.
Prior to co-founding Northstar, John was a founder of Heartstream, a Seattle-based company that revolutionized the treatment of sudden cardiac arrest with uniquely designed defibrillators that make the deployment of these devices practical in a variety of settings. In addition to his founding role, John was a member of the executive team responsible for guiding the company through formation, product development, venture financing, FDA clearance, product launch, manufacturing scale-up, an initial public offering, worldwide sales and distribution, and the sale of the company to Hewlett-Packard. The company is now owned by Philips Medical Systems.
John received a BS in industrial engineering from Stanford University and an MBA from Northwestern University's Kellogg School of Management.
Townsend & Townsend
Jim Heslin founded the firm's Medical Device Patent Group which recently placed first in a national ranking of medical device practices. He has extensive experience advising clients on how to best obtain, protect and enforce their United States and foreign intellectual property rights. He has practiced for over twenty years in this area and in that time has represented many clients in varied technological fields. His clients have developed technologies including atherectomy, angioplasty, stent delivery, arthroscopic treatments, suturing devices, ultrasound imaging, therapeutic ultrasound, gynecological devices, minimally invasive surgical equipment, implantable hearing aids, drug delivery systems, orthodontics, orthopedics, and diagnostics.
In addition to obtaining patents for clients, Mr. Heslin has extensive experience in investor due diligence and portfolio evaluation, licensing matters, preparation of patent validity and infringement opinions. He also advises clients regarding initiating in-house intellectual property protection programs.
Mr. Heslin has overseen the patent portfolios and strategies of more than twenty-five pre-public companies that have had IPO's or been acquired by public companies over the past five years.
Prospect Venture Partners
is a Managing Director of Prospect Venture
Partners. Russell co-founded Prospect Venture
Partners II and III, as dedicated life science
funds with over $1 billion in capital under
management. Prior to establishing Prospect
Venture Partners II and III, Russell was a
member of the Health Care Technology Group
at Mayfield. He joined Mayfield in 1992, served
as a Venture Partner from 1993 to 1994 and
as a General Partner from 1995-2000. Russell
played a key role in Mayfield's investment
activities in the biotechnology and medical
device sectors. As an Associate, he participated
actively in the incubation of Millennium Pharmaceuticals
and as a General Partner he was responsible
for the incubation of Intuitive Surgical Devices
both of which are now publicly traded. (NASDAQ:
Prior to Mayfield, Russell was at the University
of California San Francisco from 1984-1992 where
he was engaged in biomedical research. His work,
published in a variety of respected journals,
focused on important aspects of hepatitis B viral
replication. His descriptions of the reverse
transcription and packaging functions of polymerase
gene products merited publication in Nature.
Russell serves or has served on the Board of
Directors of Intuitive Surgical (NASDAQ: ISRG),
Hansen Medical (NASDAQ: HNSN), Opus Medical (NASDAQ:
ARTC), Orquest (NASDAQ: JNJ), Visiogen, Baxano,
Dfine, Allux Medical, SentreHEART, Portola Pharmaceuticals
and several other privately-held companies. Russell
serves as the Vice Chairman of the BOD of Interplast
and on the Genetics Advisory Council of the Harvard
Medical School-Partners Healthcare Center for
Genetics and Genomics.
Russell holds an M.D. and Ph.D. in Biochemistry
from the University of California, San Francisco
and a B.A. in Chemistry from the University of
Phil Hopper President, CEO M2 Medical
Mr. Hopper was named President and CEO of M2 Medical which is developing a drug delivery pump device in March, 2007. Previously, he served as President and CEO of LuMend, Inc., a vascular catheter product company which was acquired by Cordis Endovascular, a Johnson & Johnson Company, in September of 2005. Prior to that Mr. Hopper served as Vice President of Marketing and Sales for Radiant Medical, Vice President of Sales for Guidant Sales Corporation (spinout of Lilly MDD), Vice President of Marketing and Sales for Origin Medsystems (acquired by Eli Lilly), Vice President of NBD and Marketing for Ioptex, (acquired by Smith and Nephew), and Vice President Sales and Marketing and Commercial Operations of Lukens Medical. He started his medical device career in various marketing and sales positions with Iolab and Ethicon, both Johnson & Johnson Companies. He is a named co-inventor on fourteen medical device patents and was graduated with honors from Emporia State University. He also currently serves as Chairman of the Board of FlowMedica, a device company focused on intra-renal drug delivery to treat and prevent kidney disease.
Hutton joined Canaan Partners in 2004 as a
Venture Partner in the healthcare sector focusing
on medical devices and biotechnology. While
at Canaan, Wende has played an instrumental
role in the sales and marketing and recruiting
strategies for many healthcare clients including
Alsius, Northstar Neuroscience and ReVision
Prior to Canaan Partners, Wende was a General
Partner of Spring Ridge Ventures from 2001 to
2003, where her investments included Northstar
Neuroscience and Spine Wave. Her venture career
began at Mayfield Fund in 1993 in the Health
Care Technology Group. She served as a General
Partner at Mayfield from 1995 to 2001. During
her tenure at Mayfield, Wende incubated Heartstream,
Inc. (NASDAQ: HPQ) and Northstar Neuroscience,
working closely with those founding teams. Prior
to Mayfield, Wende held management positions
at Nellcor, Inc. and GenPharm International in
business development and marketing.
Wende sits on the boards of Alsius Corp., Apieron
Inc., BiPar Sciences, Inc., Northstar Neuroscience,
Inc. (NASDAQ: NSTR), Oculir Inc., ReVision
Optics, Inc., and Spaltudaq Corp. Her previous
board seats include Heartstream, Inc. (acquired
by Hewlett Packard), Micro Therapeutics, Inc.
(acquired by ev3, Inc.), Orquest, Inc. (acquired
by Johnson & Johnson), and SenoRx, Inc. (NASDAQ:
Mir Imran Founder InCube
Mir Imran founded InCube Laboratories in 1995 to focus on his passion: creating medical device solutions that change the standard of care in critical healthcare markets. Mir began his career as a med-tech entrepreneur in the late 1970’s, and has founded over 20 companies since those early days. Over the decades, he has become one of the world’s most successful inventors, entrepreneurs and investors in healthcare.
Mir now holds more than 200 issued patents – and is perhaps most well known for his pioneering contributions to the first FDA-approved Automatic Implantable Cardioverter Defibrillator. However Mir has invented a number of breakthrough devices that set new standards of care for their industries. Highlights include the world’s first EEG monitors, Trans-Urethral Needle Ablation (TUNA) procedures, embolic protection devices, ultrasound imaging and a host of other innovations that he commercialized through successful business ventures.
As an entrepreneur, Mir has founded over 20 medical device companies, including: Vidamed (acquired by Medtronic), Physiometrix (IPO 1996), Cardiac Pathways (IPO 1996), Advanced Cytomextrix (acquired by Oncotech 1997), Percusurge (acquired by Medtronic 2001), Reflow, Inc. (acquired 1999), Safeview (acquired by L3 2006) Intrapace ( founded 2001), Spinal Modulation (founded 2005) and Zonare (founded 1999).
As an investor, Mir serves as the Life Science Venture Partner for DFJ ePlanet, where he has led 9 investments in a range of promising ventures around the globe. In addition to his venture capital activities, Mir is an active angel investor, with a portfolio based around both medical and pharmaceutical ventures. Mir currently holds board seats with Bodymedia, Cardiovasc, Intrapace, Egeen International, Spinal Modulation, ZARS and Zonare.
Mir holds an MS in Bio-Engineering and a BS in Electrical Engineering from Rutgers, where he spent three years as a Research Specialist.
Ross Jaffe Co-Founder Versant Ventures
Ross Jaffe specializes in early-stage investing in medical devices. He brings significant clinical insight and venture capital experience to Versant’s investing efforts. Ross co-founded Versant Ventures in 1999 after spending nine years at Brentwood Venture Capital where, as a general partner, he led investments in medical devices, drug delivery, and healthcare information systems companies.
Ross is a board-certified internist, having completed his residency training in Internal Medicine/Primary Care at the University of California, San Francisco, where he remained a part-time attending physician until 1995. Before and during medical school, he was an Analyst for Lewin and Associates, a healthcare consulting firm, and a Research Associate at Dartmouth Medical School.
Ross has served as a director of St. Francis Medical Technologies (sold), Therasense (sold), Novacept (sold), Micro Interventional Systems (sold), Aradigm (public), Webster Laboratories (sold), Atrionix (sold), and Pro•Duct Health (sold). He currently serves on the boards of Insulet, Calypso Medical Technologies, Ablation Frontiers, NDO Surgical, and Acclarent. Ross earned his BA in Policy Studies from Dartmouth in 1980, his MD from Johns Hopkins in 1985, and his MBA from Stanford in 1990.
Steve Jwanouskos Consultant
Steve Jwanouskos is a graduate of the University of Minnesota with a Bachelor of Science in Rhetoric (scientific and technical writing and editing). He held increasingly more responsible positions during his 20 years in the medical device industry before going into business for himself as a full-time regulatory and clinical consultant (November 2005). Steve has garnered new product approvals for both PMA and 510(k)-regulated devices, which include permanent implants such as cardiac and intravascular stents, magnetic transponders for radiation oncology, electrophysiology and surgical ablation systems, Doppler ultrasound guidewires, ultrasound imaging catheters, laser, optical coherent tomography imaging and ultraviolet phototherapy systems. He has been an invited speaker on a variety of topics concerning regulation of medical devices. Steve and his wife, Pam, have lived in San Jose, CA for the past 15 years.
Mike Kaplan Partner Three Arch Partners
Mike Kaplan is a Partner at Three Arch Partners. Before joining Three Arch Partners Mike was a senior executive at Blue Shield of California, a $4.5 billion health plan. He served Blue Shield as Vice President Business Transformation, Vice President Corporate Development & Strategic Planning, and Regional Chief Executive for Northern California. Prior to his work with Blue Shield, Mike was a healthcare consultant at APM Incorporated (now CSC Healthcare). He began his career in investment banking with Kidder, Peabody & Co. Incorporated.
Mike holds a BS in Business Administration from Washington University where he graduated with high honors. He earned his MBA from the Stanford Graduate School of Business where he was an Arjay Miller Scholar.
Laura Knapp has worked in the medical device industry for the last twenty years, performing clinical research for small start-ups and large public companies. She has been involved in the planning and management of all aspects of device trials in the US and OUS. Ms Knapp’s experience has been in the fields of cardiac electrophysiology, vascular and heart failure, working for Medtronic, Johnson and Johnson and Paracor Medical. She is a graduate of the University of California with a BA in Biology.
Uday Kumar Founder, CMO iRhythm Technologies
Dr. Uday N. Kumar, a cardiologist and cardiac electrophysiologist by training, is the Founder and Chief Medical Officer of iRhythm Technologies, Inc., a venture-backed San Francisco medical device company focused on developing new devices and systems for cardiac rhythm monitoring. He is also an Adjunct Clinical Instructor of Cardiovascular Medicine at Stanford University, where he previously was a Biodesign Cardiovascular Innovation Fellow (’05-’06). As a Fellow there, he focused on identifying and developing solutions to unmet needs in the field of cardiac electrophysiology (EP); one of these ideas formed the basis for iRhythm Technologies, Inc., which he founded in late 2006. Prior to coming to Stanford, Uday completed fellowships in cardiac EP and cardiology at the University of California, San Francisco (UCSF) in 2005 and 2003, respectively. He previously completed his training in internal medicine in 2001 at Columbia-Presbyterian Hospital of Columbia University. From 1998-1999, he helped to start Biomedical Modeling Inc., a company that created models from imaging data using rapid prototyping techniques for use in numerous medical areas. He started work on this project when he was a student at Harvard Medical School, from which he received his M.D. in June 1998. Prior to this, he received his B.A. magna cum laude in Biochemistry from Harvard College in 1994. Uday grew up in Rhode Island and is originally from Bangalore, India.
Joshua Makower, M.D.
Founder & CEO ExploraMed
Joshua Makower, M.D. is the Founder & CEO of ExploraMed Development, LLC, a medical device incubator and is also a Venture Partner with New Enterprise Associates. Dr. Makower serves as a Consulting Associate Professor of Medicine at Stanford University Medical School and is Co-Founder of Stanford’s Biodesign Innovation Program. He has played numerous roles in early stage ventures including Founder, Chairman and Chief Technical Officer of TransVascular, Inc. EndoMatrix, Inc. and was Founder and Manager of Pfizer’s Strategic Innovation Group. Dr. Makower holds a MBA from Columbia University, an MD from the NYU School of Medicine, and a SB degree in Mechanical Engineering from MIT. Dr. Makower also serves on the Board for Acclarent, Inc., NeoTract, Inc and Vibrynt, Inc., and Intrinsic Therapeutics, Inc.
De Novo Ventures
Joe Mandato joined De Novo Ventures as a Managing Director in March 2003. Prior to joining De Novo, Joe served as Chairman of Confer Software, a developer of software used to create efficiencies and streamline processes in healthcare. He was also the CEO of ACompany Orthodontics, a leveraged purchase from Johnson & Johnson, subsequently acquired by Sybron Dental. Prior to that, he served as President/CEO of Origin Medsystems, a developer of minimally invasive surgical devices for use in general, cardio-thoracic, and ob-gyn surgery, which was acquired by Eli Lilly & Company in 1992 and spun out as one of the units which formed Guidant Corporation in 1995. At Guidant, Mr. Mandato served as a member of the founding management committee and CEO of two of its five operating units, Origin and Heart Rhythm Technology. He also co-founded and served as CEO of Gynecare, a women’s health spin-out of Guidant. Subsequent to his tenure at Guidant, he served as an Entrepreneur-in-Residence at Mayfield Fund, a venture capital firm. Earlier in his career, he was CEO of Ioptex Research, a developer of intraocular lenses used in cataract surgery, which was acquired by Smith & Nephew PLC. He joined Ioptex from Cilco AG in Zug, Switzerland, the Europe, Middle East, and Africa headquarters of a unit of Rorer Group, where he served as CEO. He began his career in healthcare as a Captain in the U.S. Army Medical Service Corps.
He received his Doctorate of Management from Case Western Reserve University, and serves on its Board of Trustees. His research focused on the evolving role of boards in ensuring effective governance. He serves on the adjunct faculty of The University of San Francisco’s Graduate School of Management and co-teaches the course Medical Device Innovation at Stanford University. He also serves on the boards of The Institute of International Education and Save the Children.
John joined Delphi Ventures as a General Partner in 2003 and focuses on medical device and diagnostic investments.
Prior to joining Delphi, John was President and CEO of EndoTex Interventional Systems, Inc. a development stage, venture backed, start-up company where he redirected the technology, resized the team and raised more than $50.0 million over six years through a series of venture capital, technology licensing, and corporate partnership financings. From 1988 to 1997, John held a variety of senior management positions including President and General Manager at EP Technologies, Vice President of Operations at both Boston Scientific Corporation and Cardiovascular Imaging Systems (CVIS). While at CVIS, John was a key member of the senior management team during the Company's IPO and eventual acquisition by Boston Scientific Corporation.
Allan May Founder Life Science Angels
Allan May is a founder of Life Science Angels (www.lifescienceangels.com), the largest angel organization in the U.S. focused solely on early stage medical device and life science start-ups, and comprised solely of high net worth individuals with extensive backgrounds in medical device or biotech operations. In addition to 120 serial entrepreneurs and founders, LSA membership includes a number of scientists, physicians and engineers with extensive life science credentials, 18 major venture capital firms specializing in life science investments, and 20 sponsors, who are all organizations focused on providing services to the life science industry. Since 2005, LSA has invested over $12M in 18 early stage companies, and attracted in excess of $260M in contemporary or follow-on venture capital.
In 2007, along with renowned inventor, entrepreneur and cardiologist, Dr. Thomas Fogarty, Allan has co-founded a $100M venture fund Emergent Medical Ventures solely focused on life science investing.
In addition, Allan has been a founder, board member or CEO of a number of early stage companies in the life science arena. He lectures frequently on trends and developments affecting biotech and life science investing.
Morrison & Foerster
Mayer is an associate in the Medical Device
group and co-founder of the Venture Intellectual
Property Group. She has worked extensively
in performing both venture side, and investor
and company sides due diligences. Ms.
Mayer has performed due diligences on potential
investments, which range in size from small
seed investments to large acquisitions, and
which span the medical device, drug delivery,
and pharmaceuticals fields. Ms. Mayer
now regularly serves as a principal contact
to many of the VIPSM group’s venture
capital clients, and has been instrumental
in expanding the venture side due diligence
practice. Ms. Mayer has significant experience
in prosecuting patent applications for medical
device and drug delivery clients and in providing
strategic advice on patent portfolio management. Ms.
Mayer also provides technical and legal support
to Morrison & Foerster’s litigators
on life science litigation matters.
Mayer received her J.D. magna cum laude from
Boston University with a concentration in intellectual
property law, and her B.S. in chemical engineering magna
cum laude from the University of Arizona.
J. Casey McGlynn
Chairman of the Life Sciences Group
Wilson Sonsini Goodrich and Rosati
Casey McGlynn is a partner at Wilson Sonsini Goodrich & Rosati and a member of the firm's Policy Committee. Since joining the firm in 1978, he also has been a member of the firm's Executive, Nominating, and Compensation Committees. Casey's practice focuses on the organization, funding, and corporate representation of companies in the information technology, life sciences, and telecommunications industries.
Casey is a nationally recognized leader in the representation of start-up and growth technology companies. He assists his clients in meeting their financing needs through introductions to an extensive network of angel investors, financiers, venture capitalists, corporate partners, and investment bankers. He has experience representing dozens of companies that have made successful initial public offerings and secondary offerings.
As a strategic business partner, Casey offers focused resources and capabilities to meet the most critical needs of start-up and emerging growth companies, including private and venture capital financings, public offerings, university licensing, and strategic collaborations. He frequently is called upon to structure and negotiate mergers and acquisitions, licensing arrangements, and domestic and international strategic corporate alliances, as well as other innovative financing arrangements.
Casey is a contributor to magazines and newsletters focused on angel and venture investing, and frequently speaks on issues relating to the organization and funding of new ventures.
Dana Mead Partner Kleiner Perkins Caufield & Byers
Dana Mead joined Kleiner Perkins Caufield & Byers as a partner in May 2005 to work in the life sciences practice.
For the past 23 years, Dana's career has focused on identifying new medical technologies, developing new markets and therapies, and building world-class management teams. He has worked with physician thought leaders around the world representing 10 different medical specialties. At KPCB, Dana leverages experience gained from his venture-funded, start-up management roles and board participation to support entrepreneurs and innovators dedicated to making a real difference in the lives of millions suffering from life-limiting disease.
Prior to joining KPCB, Dana was President of Guidant Vascular Intervention, a fully integrated billion dollar division with over 4500 employees. Since joining Guidant in 1992, he held positions of increasing responsibility including Vice President and General Manager, Cardiac & Vascular Surgery; Vice President and General Manager, Stents, Vascular Intervention Group; President, Japan and A/P Operations based in Tokyo; and Vice President, Corporate Relations and Policy with responsibility for investor relations, corporate communications, corporate marketing and public policy initiatives. Prior to joining Guidant, Dana worked in various sales and marketing roles at Allergan, Inc. and Johnson & Johnson. A native of Connecticut, Dana received his Bachelor's degree from Lafayette College and holds an MBA degree from the University of Southern California. Dana serves on the boards of the California Healthcare Institute (CHI), the Cardiovascular Research Foundation (CRF), AesThera, Inc., Corventis, Inc., Sinexus, Spotlight Surgical, Navigenics, Synvascular, OtisMed Corporation and Lucille Packard Children's Hospital (LPCH).
David Miller received his BSE degree in Civil Engineering from Princeton University in 1997 and obtained an MS in Civil Engineering from Stanford in 1998 and an MS in Mechanical Engineering at Stanford in 2001. David was also on the design and engineering team for the tallest roller coaster in the world -- the Steel Dragon 2000 in Japan. After completing the Stanford Biodesign fellowship he consulted at several medical device start-ups before co-founding InnoSpine, Inc. which was acquired by Kyhpon in 2006. He has been named as an inventor on over 20 medical device patent applications.
Eric Miller Vice President Baxano, Inc
Eric Miller is the Vice President of Marketing and Business Development at Baxano, Inc, an early stage spine company focused on treating neurovascular impingement. Mr. Miller joined Baxano Inc in August 2006 from Intuitive Surgical where he held the position of Senior Vice President of Marketing. Prior to this, Mr. Miller was President of Optimize Inc, a venture-financed medical device start-up and, for 11 years held a variety of senior sales, marketing and business development positions with United States Surgical Corporation. Mr. Miller received his Bachelor’s and Master’s degrees in health sciences and applied physiology from The Ohio State University.
Stanford Biodesign Program
Sandra Miller brings more than 12 years of experience in working with medical device physician inventors and entrepreneurs to her current position as Associate Director, Technology Transfer, for the Stanford Biodesign Program. Sandra has been instrumental in the development and implementation of several medical technology courses, fellowships and programs at the interface of industry and academia. Her focus with the Biodesign Program is to develop biomedical technology innovation educational programs and resources, particularly in the areas of technology transfer and entrepreneurship. In her role as a liaison for the Biodesign Program to Stanford’s Office of Technology Licensing, OTL, Sandra manages a medical device portfolio and facilitates the efforts of Stanford faculty and student inventors developing medical technologies. With faculty Richard Popp and Paul Yock, Sandra has recently implemented a pathway for Stanford students to participate in the U.S. Food & Drug Administration’s Medical Device Fellowship Program through the Center for Devices and Radiological Health. Sandra also manages Biodesign’s Industry Relations and Career Services activities.
She is a founding member of the Stanford Entrepreneurship Network, whose mission is to support entrepreneurship education, research and collaboration campus-wide. Sandra has produced physician education video series on revolutionary interventional cardiology innovations such as intravascular ultrasound (IVUS – Paul G. Yock, MD, inventor) and directional coronary atherectomy (DCA – John B. Simpson, PhD, MD, inventor). She holds an MBA degree from Pepperdine University.
Milne SV Life Sciences Advisers
Milne joined SV Life Sciences Advisers in 2005
with twenty years of operating experience in
several leading medical device corporations.
His primary investment focus is the medical
device sector where he has made six investments
since joining the firm. David currently serves
on the boards of AqueSys, Abdominis, CardioMind,
EBR Systems, Entellus, OsteoLign, Sadra Medical
and Spinal Kinetics. He also serves as an advisor
to The Innovation Factory, an Atlanta-based
medical device incubator, and to Intersect
Partners, a west coast-based technology accelerator.
Prior to SV Life Sciences, David spent twelve
years at Boston Scientific Corporation. Since
1999, he held the position of Vice President
of Corporate Business Development and was responsible
for over 50 transactions totaling nearly $2
billion consisting of acquisitions, equity
investments and development partnerships. In
this role he was a member of the Board of Directors
of eight early stage medical devices companies
including Cameron Health, NorthStar Neuroscience,
CryoVascular Therapeutics and 3F Therapeutics.
Prior responsibilities at Boston Scientific
included executive positions in several technology
and market development groups in both the U.S.
and as an expatriate in Europe. He has also
held positions in Corporate Planning, Product
Management and Sales with Becton Dickinson,
Inc. and Parker Laboratories.
David holds an MBA from New York University
and a BS in Biochemistry from Rutgers University.
Suzan Anne Moser Vice President NeoTract
Suzan Anne Moser serves as Vice President of Clinical and Regulatory Affairs for NeoTract, Inc. of Pleasanton, CA. She has over 20 years of clinical study experience in the medical device industry treating urologic, electrophysiologic, cardiac, and vascular diseases. Mrs. Moser previously served as Vice President of Clinical and Regulatory Affairs at IntraPace, Inc., working on a medical device for obesity. She planned and initiated successful heart failure clinical trials in Europe and the United States for Paracor Medical, Inc. As Vice President of Clinical and Regulatory Affairs and Quality Assurance at Atrionix, Inc. (acquired by Johnson and Johnson), she lead successful clinical study and quality system efforts that resulted in CE Mark and other regulatory approvals. She also performed clinical studies to help bring to market the first and other implantable defibrillators, pacemakers, cardiac ablation systems, and vascular stent grafts during her tenure in management positions at Medtronic AneuRx, Inc., CardioRhythm, Inc. (acquired by Medtronic, Inc.), and Intec System, Inc. (acquired by Eli Lilly, now Boston Scientific, Inc.) Mrs. Moser earned an M.B.A. from the University of the Minnesota, a B.S.N. from the University of the State of New York, and a Diploma in Nursing from Barnes Hospital School of Nursing.
Bhairavi Parikh has deep domain expertise in the development of medical biosensors with numerous published articles and one issued patent. She has designed and developed a sensor for the measurement of therapeutic inhaled nitric oxide and led the instrumentation team for medical device clinical studies while at the University of Massachusetts Division of Cardiothoracic Surgery. Bhairavi was also involved in new product development at Natus Medical. Bhairavi has a PhD in Biomedical Engineering from a joint program with the Worcester Polytechnic Institute (WPI) and University of Massachusetts Medical Center. She also earned an MS in Biological Engineering from the University of Connecticut and a BS in Biochemistry from the University of New Hampshire.
Rodney Perkins Founder, chairman, Sound ID et al
Dr. Rodney Perkins is an internationally know otologic surgeon who has participated actively in the development of multiple successful medical device companies. He is the founder of the California Ear Institute at Stanford and a Clinical Professor of Surgery at Stanford.
Dr. Perkins also founded three public companies: Laserscope and ReSound Corporation of which he was CEO and chairman and Collagen Corporation.
He was founder, chairman and CEO of Cohesion Corporation which was sold to Collagen Corporation and a founder, CEO and chairman of Novacept which was sold to Cytyc Corporation.
Dr. Perkins is currently active as the founder and chairman of Sound ID and Pulmonx, chairman of Surgrx and DFine and founder, chairman and CEO of EarLens, a new venture developing a novel method of sound transmission.
Dr. Perkins has eighteen issued patents. He attended Indiana University and Oxford for his medical education and served a surgical residency at Stanford University School of Medicine.
Plain The Foundry
Hank Plain joined Morgenthaler Ventures in 2007 after more than 25 years in the life science industry, including co-founding eight medical device start-ups and directing the exits of four companies with a combined value well in excess of $1 billion. He is based in Menlo Park, California and will focus on medical device investments.
Hank is the vice chairman of The Foundry, the premier medical device incubator based in Redwood City, California, where he co-founded Ardian, Cabochon Aesthetics, Cierra, Emphasys Medical, ForSight Labs, Satiety, Transcend and XTENT (XTNT). He also served as president and CEO at Perclose, Inc. from 1993 to 2000, during which he led the company to $100 million in sales and managed the company’s successful IPO and acquisition in 1999 by Abbott Laboratories for $650 million. He was chairman of Embolic Protection, where he helped negotiate the acquisition of the company in 2001 by Boston Scientific for $200 million. He also served as a director at TransVascular until Medtronic acquired the company in 2003 for an undisclosed amount. Hank serves as chairman of XTENT, which completed a successful IPO in February of this year. Previously, Hank worked at Eli Lilly for 12 years in various management positions.
Dr. Stuart Portnoy joined the group in August of 2007. He has expertise in regulatory strategy for medical technologies, product development for drug/device and biologic/device combination products, assisting clients with strategy and development of preclinical testing, and designing clinical protocols and drafting other documents that comply with FDA regulations and expectations. He has served as a Medical Officer and Clinical Reviewer at Center for Device Evaluation and Radiological Health and was most recently a medical device consultant for PharmaNet.
Erica Rogers President, CEO Allux Medical
Erica Rogers is the President and CEO of Allux Medical, a company formed out of a medical device incubator backed by Prospect Ventures, Three Arch partners, and Venrock. Allux is developing novel technology for the treatment of hyper-reactive airway. Erica is also the co-founder of Visiogen, an ophthalmic company developing a dual optic accommodating lens. She holds over thirteen issued or pending patents in the medical device and nanotechnology. Erica spent over 12 years at Boston Scientific, in sales and marketing positions. She has extensive experience in cardiovascular, peripheral vascular, and neurovascular interventional medicine. After a degree in zoology, she began her career at the Upjohn Company.
Vahid Saadat Founder, CEO Voyage Medical
Vahid Saadat has over 20 years of experience in the medical device industry. Currently Mr. Saadat is the founder and CEO of Voyage Medical in Santa Clara, California which he founded in February of 2006.
Previously, Mr. Saadat co-founded and was the president of USGI Medical, Inc a gastrointestinal device company backed by Alta partners and Interwest partners. Mr. Saadat is also a co-founder and a board member of Baxano, Inc, an orthopedic and spine Company backed by Prospect Venture Partners and Three Arch Partners. Baxano was founded in July of 2005.
Before USGI Medical, Mr. Saadat served as the president and CEO of AngioTrax, founded in 1997. AngioTrax developed myocardial revascularization technologies for the treatment of ischemic heart disease.
Prior to AngioTrax, Mr. Saadat served as Vice President of Research and Development at Gynecare, Inc. Gynecare was acquired by Johnson and Johnson in 1997. Prior to Gynecare, Mr. Saadat was Senior Vice President of R&D and operations at Trimedyne, Inc., where he managed the development of new laser technologies. Mr. Saadat also helped found Cardiac Science, which developed an automatic defibrillator device and is now a public company.
Mr. Saadat holds a BS and MS in Electrical and Biomedical engineering from the University of Texas at Austin. He has many scientific publications to his credit and is inventor on over 200 issued and pending patents.
Amr Salahieh Founder Sadra Medical
Amr Salahieh is an experienced medical device entrepreneur with over 14 years of experience. He founded Sadra Medical with the vision to significantly improve valve replacement therapy by facilitating a minimally invasive, elegant procedure.
Previously, as VP of R&D at Boston Scientific, Amr brought the FilterWire EX to the US market. He played an active role in building EPI and in its acquisition by Boston Scientific. He has significant R&D management experience from his engineering consulting firm, Sobek Medical LLC, and from both CardioThoracic Systems and Guidant.
Amr is inventor/co-inventor of more than 36 US issued or filed patent applications. He holds two degrees, one in Biomedical Engineering and the other in Electrical Engineering from Case Western Reserve University in Cleveland, Ohio.
Highland Capital Partners
Bijan Salehizadeh is a Partner at Highland Capital Partners. Based in Highland’s Menlo Park office, Bijan Salehizadeh partners with entrepreneurs and management of medical devices and biotechnology healthcare companies. He is or has been actively involved in Highland's investments in BAROnova, Conor Medsystems (IPO; acquired by Johnson & Johnson), Hyperion, Magen BioSciences, Pervasis Therapeutics and Predictive Biosciences.
Prior to joining Highland, Bijan spent several years in marketing and strategic planning at Medtronic Vascular, a world leader in medical technology. Before Medtronic, Bijan was the Director of Business Development for HealthCentral, a venture-backed start-up that went public in 1999.
During his medical training, Bijan conducted research in minimally invasive heart valves and left ventricular assist devices, and his work was published in several peer-reviewed scientific journals. He also served as a researcher at the National Heart, Lung, and Blood Institute where he investigated coronary artery disease.
Bijan also previously served as a member of the Kauffman Fellows program.
Bijan holds an A.B. of Molecular Biology from Princeton University, an M.S. of Health Policy and an M.D. of Medicine from Columbia University, as well as an M.B.A. from Harvard Business School.
Alan Schaer Silk Road Medica
Alan brings over 18 years of medical device engineering and management experience to his current position at Silk Road Medical, a new venture created from The Vertical Group. Upon graduating cum laude in Mechanical Engineering from Cal Poly, San Luis Obispo, Alan’s medical device career began at ACS/Guidant where he developed PTCA balloon catheters. After 4 years, Alan joined the founding team of Cardima where he brought novel electrophysiology devices to market and saw the company through its IPO. Alan then joined the founding team of Atrionix, where he developed an ultrasonic therapy for Atrial Fibrillation until the company’s sale to J&J in 2001. Most recently, Alan led project teams at Paracor Medical, where he oversaw the development and clinical implementation of an implant and delivery system designed to treat Congestive Heart Failure and protect against ventricular tachyarrhythmias.
Kearny Venture Partners
Jim Shapiro has been a general partner of Kearny Venture Partners and its predecessor funds since January 2000. He focuses on investments in the Medical Device industry. Jim currently serves on the boards of directors of CVRx, Eyeonics, Hansen Medical, SpinalMotion and TranS1. He is a co-founder of SpinalMotion.
Jim has previously served on the boards of directors of companies including Appriva (acquired by eV3 [NASDAQ: EVVV]), Fox Hollow Technologies [NASDAQ: FOXH], LuMend (acquired by Johnson and Johnson [NYSE: JNJ]), TriVascular (acquired by Boston Scientific [NYSE: BSX]) and X Technologies (acquired by Guidant [NYSE: BSX]).
From 1984 to 1999, Jim led Alex. Brown's healthcare investment banking practice on the West Coast, providing financing and M&A advisory services to both emerging growth and established healthcare companies. During this time he developed a deep network in the medical device space, including entrepreneurs, clinicians, lawyers and venture capitalists involved in emerging company creation and management. In addition, he developed relationships with the natural acquirers of these companies, both as clients and as counterparties to clients he represented as sellers. The resultant relationships have enabled him to provide differentiated value to portfolio companies of the funds.
Before joining Alex. Brown, Jim was an associate at Goldman Sachs and a financial analyst at Bank of America. He holds an A.B. with laboratory research honors from Princeton University, and an M.B.A. from the Stanford University Graduate School of Business.
Jay Shukert Consultant Chief Financial Officer
Jay Shukert has more than 10 years of experience as a consultant chief financial officer to biotechnology and medical device companies. In this role, he has managed equity and debt financings, raising more than $235 million, developed strategic plans and implemented financial strategies, developed product evaluation methods which considered financial resources, potential markets and FDA guidelines and reviewed and monitored FAR, SBIR and GPRA reporting issues.
Previously, Jay held senior finance positions at CV Therapeutics, Neurex Corporation, Genentech and Arthur Andersen. He received his master's of business administration from the University of California, Berkeley and a bachelor's degree in civil engineering from University of Pennsylvania.
Carl Simpson Coronis Medical Ventures
Carl Simpson has worked in the medical/medical device arena for over 40 years.
He supported his way through undergraduate school working as an x-ray technician at El Camino Hospital. In addition he supported his way through graduate school working at Stanford in cardiovascular medicine.
His undergraduate training is in Microbiology and Biochemistry. His graduate degrees are in Electrical Engineering/Computer Science and an MBA, both from the University of Santa Clara.
After graduate school and a short period working for Hewlett-Packard's medical business group, Carl began an unanticipated excursion into becoming a medical device entrepreneur. With John Simpson, MD, PhD, and Ray Williams, Advanced Cardiovascular Systems (ACS) was formulated and was Carl's first entrepreneurial effort. Needless to say ACS was very successful, the company was sold to Lilly in 1984 and spun-off into Guidant in 1994. ACS became the University of Medical Devices for Silicon Valley, giving birth to over 100 medical devices companies. Recently Guidant has been sold to Boston Scientific and Abbott Vascular.
ACS created the experience, motivation and entrepreneurial drive to launch into a career of working with other entrepreneurs in establishing over 16 medical device companies. Carl has been on the board of multiple medical device companies and worked with Versant Ventures for four years learning the VC business and assisting them in defining new companies for future investments.
With multiple start-up companies under his belt, understanding the VC business models, and 40 years of operational and clinical experience, Carl is uniquely situated to contribute to the success of early stage medical device companies through the Coronis Medical Ventures incubator.
Jackson Streeter Founder PhotoThera
After evaluating infrared therapeutic laser technology for the U.S. Navy, Dr. Jackson Streeter founded PhotoThera and has built a successful medical device company from the ground up. He is one of the pioneering scientists in the area of using infrared lasers for the treatment of injured tissue and is the inventor of five issued patents and has multiple patents pending. Dr. Streeter serves on the Board of Directors and is also the co-chairman of the medical device committee of BIOCOM.
Dr. Streeter earned his BS degree in Biology, graduating with High Distinction from the University of Nevada Reno and received his MD from the University of Nevada School Of Medicine. He then went on to serve as an Officer in the U.S. Navy, completing a general surgery internship at Naval Regional Medical Center Portsmouth, Virginia and then primary Flight School at Naval Air Station Pensacola, Florida. Dr. Streeter was the first Naval Flight Surgeon selected as a Top Gun staff instructor. He has over 400 flight hours in the F/A 18 Hornet and F-14 Tomcat. He has been awarded the Navy Achievement Medal (2) and the Navy Commendation Medal.
Karen D. Talmadge, Ph.D. co-founded Kyphon and has served as a member of our board of directors since inception. She has also served as our Chief Science Officer since June 2003 and as Executive Vice President since November 1998. From January 1994 to November 1998, Dr. Talmadge served as our President, Chief Executive Officer and Treasurer. Dr. Talmadge holds an A.B. in Biology from Bryn Mawr College and a Ph.D. in Biochemistry and Molecular Biology from Harvard University.
Hira Thapliyal President, CEO VytronUS, Inc.
Hira V. Thapliyal, Ph.D. is the President & CEO of VytronUS, Inc. VytronUS is developing products in cardiovascular field. Prior to VytronUS, Dr. Thapliyal was the cofounder of ArthroCare Corporation in 1993 (NASD:ARTC), and served as President and CEO from inception to July 1997. ArthroCare develops devices for arthroscopic, ENT, and spine surgery. From 1989 to 1993, Dr. Thapliyal was President and CEO of MicroBionics, Inc., a privately held company developing an in-vivo continuous blood gas monitor. In 1986, Dr. Thapliyal Co-founded Cardiovascular Imaging Systems, Inc. (CVIS) with Dr. Paul Yock and Dr. John Simpson and served as its President until 1988. CVIS, now a division of Boston Scientific Corp., develops and markets catheters for ultrasonic intraluminal imaging (IVUS) of human arteries. From 1984 to 1986, Dr. Thapliyal was Vice President of Engineering at Devices for Vascular Interventions (DVI), now a part of Guidant Corporation. DVI is a leader in marketing atherectomy systems for treatment of atherosclerotic disease. Hira is currently a member of the advisory board of the Department of BioEngineering, University of California, Berkeley, and the advisory board of the Materials and Science and Engineering Department at Cornell University.
Stephen Thau Heller Ehrman
Stephen Thau has been a member of Heller Ehrman’s Venture Law Group since 2003.
Mr. Thau represents emerging companies and venture capital firms, with an emphasis on venture capital financings, corporate partnerships, mergers and acquisitions, and public offerings. He works with clients in life sciences and biotechnology (including Anacor Pharmaceuticals, Catalyst Biosciences, Horizon Therapeutics and Threshold Pharmaceuticals), medical devices and diagnostics (including Adeza Corporation, Baxano, DURECT Corporation, Revivant and Visiogen) and software and communications technology (including Coremetrics, Digital Fountain and Ingenuity Systems).
Prior to developing his corporate practice, Mr. Thau practiced intellectual property litigation and securities litigation with a national law firm. Before law school, Mr. Thau was a business strategy consultant with a national strategy consulting firm.
Harvard University (A.B., Biology, magna cum laude, 1989); Stanford Law School (J.D., 1994); Order of the Coif; Managing Editor, Stanford Law Review. Mr. Thau is a former law clerk to the Honorable Vaughn R. Walker, of the U.S. District Court in the Northern District of California.
Sean Tunis Founder, Director Center for Medical Technology Policy
Sean Tunis, MD, MSc. is the Founder and Director of the Center for Medical Technology Policy in San Francisco, where he is working with health care decision makers and stakeholders to support the rapid evaluation and effective use of new medical technologies. He is also a Principal at Rubix Health, which consults with early-stage life sciences companies on reimbursement strategy deigned around developing reliable evidence of product value.
Through September of 2005, Dr. Tunis was the Director of the Office of Clinical Standards and Quality and Chief Medical Officer at the Centers for Medicare and Medicaid Services (CMS). In this role, he had lead responsibility for clinical policy and quality for the Medicare and Medicaid programs, which provide health coverage to over 100 million US citizens. Dr. Tunis supervised the development of national coverage policies, quality standards for Medicare and Medicaid providers; quality measurement and public reporting initiatives, and the Quality Improvement Organization program. As Chief Medical Officer, Dr. Tunis served as the senior advisor to the CMS Administrator on clinical and scientific policy. He also co-chaired the CMS Council on Technology and Innovation.
Dr. Tunis joined CMS in 2000 as the Director of the Coverage and Analysis Group. Before joining CMS, Dr. Tunis was a senior research scientist with the Lewin Group, where his focus was on the design and implementation of prospective comparative effectiveness trials and clinical registries. Dr. Tunis also served as the Director of the Health Program at the Congressional Office of Technology Assessment and as a health policy advisor to the U.S. Senate Committee on Labor and Human Resources, where he participated in policy development regarding pharmaceutical and device regulation.
He received a B.S. degree in History of Science from Cornell University, and a medical degree and masters in Health Services Research from the Stanford University School of Medicine. Dr. Tunis did his residency training at UCLA and the University of Maryland in Emergency Medicine and Internal Medicine. He is board certified in Internal Medicine and holds adjunct faculty positions at Johns Hopkins and Stanford University School of Medicine.
Brad Vale Vice-President Johnson & Johnson Development Corporation
Dr. Brad Vale is a Vice-President in Johnson & Johnson Development Corporation, Johnson & Johnson’s venture capital subsidiary. His healthcare investments focus on areas of potential strategic interest to JNJ with an emphasis on medical devices.
He completed his PhD at Iowa State University in Biomedical Engineering and his DVM at Washington State University. He was at Ethicon from 1982 to 1989, including two years with a spinout, Warren Labs, and joined J&J’s Corporate Office of Science and Technology in 1989.
He moved into venture capital, joining Johnson & Johnson Development Corporation in 1992, and in July of 1997 moved to California to establish JJDC’s Silicon Valley office. Some recent investments from 2001 to the present include: Northstar, NeuroPace, BioRexis, Biolex, Ilypsa, Glysens, CVRx, Direct Flow and a spinout of Alza drug delivery technology, Macroflux.
Kevin Wasserstein Versant Ventures
Kevin Wasserstein specializes in investing and building early-stage medical device companies at Versant. Kevin currently serves as a director for Cellutions, NDO Surgical, and Rox Medical, and as a board participant for Acclarent, LipoSonix, NeoGuide Systems, Second Sight Medical, and The Innovation Factory. Kevin also serves as an advisor to numerous entrepreneur groups.
Kevin has more than fourteen years of venture capital and operating experience in medical device and high technology companies. Prior to joining Versant, Kevin served in a variety of marketing and business development roles at Guidant Corporation, most recently acting as the Director of Marketing in Guidant's Cardiac Surgery Group managing market/product development and launch initiatives. Kevin also served as Senior Global Product Manager in Guidant's Peripheral and Carotid Group, during which he developed and launched several first-generation stent and embolic protection devices. Previously, in Guidant's Compass Business Development Group, Kevin was involved in acquisition, licensing and investment activities with both private and public medical device companies, and in formulating corporate strategies to develop innovative medical technologies. Kevin's operational experience also includes business development at Heartstream, and engineering design and engineering management responsibilities at Hughes Aircraft Company.
Kevin holds both Bachelor's and Master's degrees in Mechanical Engineering, as well as an MBA, all from Stanford University.
De Novo Ventures
Jay Watkins is a Managing Director at De Novo Ventures. Prior to joining De Novo in 2002, Jay was a co-founder of Origin Medsystems, a venture-funded medical technology start-up that was purchased by Eli Lilly & Company in 1992. When Eli Lilly divested its medical device businesses to form Guidant in 1995, he became a member of the corporation’s management committee, serving in this role from 1995-2002. During this time, he served as president of numerous divisions, including the Minimally Invasive Surgery Group. In addition, Jay was the President of Compass, Guidant Corporation’s corporate business development and new ventures group. Prior to founding Origin, Jay held management positions in several start-ups, including Microgenics Corporation, and was a consultant with the international consulting firm of McKinsey & Company. He has been a member of the board of directors of several public companies, including Gynecare, Cardiogenesis, and Rita Medical. Jay received his MBA from Harvard University and his undergraduate degree from Stanford University.
John White Sales Representative Boston Scientific
John White is currently a Sales Representative for Boston Scientific Cardiac Rhythm Management. Prior to joining Boston Scientific, John was one of the 2006 Stanford Biodesign Innovation Fellows. While at Stanford, John filed several patents in the cardiovascular and ENT space. John's patents have been been utilized as founding technology for two venture backed companies in the cardiovascular space. John also has three years of management consulting experience with Deloitte, where he focused on the medical device industry. John has an MBA from Stanford University and a BA from Dartmouth College in both history and economics.
N. Parker Willis Vice President EBR Systems
N. Parker Willis has a B.S. in Electrical Engineering from the University of California, San Diego, and M.S and PhD. Degrees in Electrical Engineering from the University of Illinois. He has been in the medical device industry for 15 years, specializing in cardiac electrophysiology, medical imaging, 3D navigation systems, and biomedical signal processing. He is currently Vice President, Research, at EBR Systems. He has authored approximately 30 US patents.
Paul G. Yock, M.D.
Martha Meier Weiland Professor of Medicine and Mechanical Engineering
Co-Chairman, Department of Bioengineering
Paul Yock is the Martha Meier Weiland Professor of Medicine and Mechanical Engineering (by courtesy) and Co-Chair of Stanford’s new Department of Bioengineering. Dr. Yock began his faculty career as an interventional cardiologist at UC San Francisco and then moved to Stanford in 1994.
Dr. Yock is known for his work in inventing, developing and testing new devices, including the Rapid Exchange ™ balloon angioplasty system, which is now the primary system in use worldwide. He also invented a Doppler-guided access system known as the Smart Needle™ and PD-Access™. The main focus of Dr. Yock’s research program has been in the field of intravascular ultrasound. He authored the fundamental patents for intravascular ultrasound imaging and conducted the initial clinical trials. In 1986 he founded Cardiovascular Imaging Systems, which was acquired by Boston Scientific in 1994. Dr. Yock has authored over 40 US patents, 300 peer-reviewed publications, chapters and editorials, and a textbook.
Current research interests of Dr. Yock’s group include development and testing of catheter-based delivery systems for cardiac cell transplantation and new catheter and molecular imaging techniques for cardiology.
Dr. Yock also directs the Program in Biodesign, a unit of Stanford’s new Bio-X initiative that focuses on invention and technology transfer related to biomedical engineering.
Reza Zadno President, CEO Visiogen
Reza Zadno, PhD is President and CEO of Visiogen, Inc., an Irvine, CA based company developing a dual-optic accommodating intraocular lens. Prior to Visiogen, Reza was an entrepreneur in residence at Three Arch Partners. He was a co-founder of PercuSurge, Inc., where he served as VP of R&D and CTO until August 2000. PercuSurge developed, manufactured and marketed systems to contain and remove dislodged emboli during percutaneous vascular interventions, and was acquired by Medtronic in 2000.
Prior to PercuSurge, Reza was with Cardiac Pathways Corp. from the company's very early development stage until 1995, and served as the Director of Advanced Development Group. Cardiac Pathways developed, manufactured and marketed mapping and ablation systems for treatment of arrhythmia (IPO in 1996 and acquired by Boston Scientific in 2001).
From 1984-1992 Reza was with Raychem Corp. and worked in France, Belgium and USA as R&D Engineer and Project Manager. At Raychem, he developed Nitinol alloys and products in applications such as laparoscopy instruments, guide wire materials, dental arches, and industrial products including electrical connectors.
Reza holds MSc and PhD in Metallurgy from Ecole Nationale Superieure des Mines de Paris and has filed more than 100 US and international patent applications.